Effects of Mibefradil on Large and Small Coronary Arteries in Conscious Dogs: Role of Vascular Endothelium

Publisher Website
Google Scholar
Abstract
Summary The systemic and coronary hemodynamic effects of mibefradil, a “nondihydropyridine” calcium antagonist acting on both L- and T-type calcium channels, were investigated in chronically instrumented conscious dogs before and after local endothelium removal of the circumflex coronary artery by angioplasty. After intravenous infusion, mibefradil (0.2 mg kg-1 min-1) decreased mean arterial blood pressure (MAP; -15 ± 1%), increased heart rate (HR; 58 ± 9%), and coronary blood flow (CBF; 103 ± 14%) (all p < 0.05). Before endothelium removal, mibefradil increased the diameter of the left circumflex epicardial coronary artery (LCX) by 7.8 ± 1.2% from 3,006 ± 219 μm, but this dilatory effect was significantly reduced by 69% (p < 0.001) and 45% (p < 0.01), 3 and 21 days after endothelium removal, respectively. Mibefradil also reduced by 46% (p < 0.01) the potent coronary constrictor effect of ergonovine (300 μg intravenous bolus). These results demonstrate that mibefradil is a potent dilator of large and small coronary arteries in conscious dogs and that ≈30% of its dilatory effect on large coronary artery is endothelium-independent. In addition, mibefradil prevents ergonovine-induced epicardial coronary constriction.